NASDAQ:MCRB Seres Therapeutics Q1 2026 Earnings Report $5.62 -0.08 (-1.40%) Closing price 04:00 PM EasternExtended Trading$5.58 -0.04 (-0.62%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Seres Therapeutics EPS ResultsActual EPS-$2.08Consensus EPS -$1.88Beat/MissMissed by -$0.20One Year Ago EPSN/ASeres Therapeutics Revenue ResultsActual Revenue$0.36 millionExpected Revenue$0.36 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/ASeres Therapeutics Announcement DetailsQuarterQ1 2026Date5/5/2026TimeBefore Market OpensConference Call DateTuesday, May 5, 2026Conference Call Time7:00AM ETUpcoming EarningsSeres Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Seres Therapeutics Earnings HeadlinesWe're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn RateJune 13 at 12:49 AM | finance.yahoo.comSeres Therapeutics Sets 2026 Annual Shareholder Meeting DateJune 9, 2026 | theglobeandmail.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.June 15 at 1:00 AM | Banyan Hill Publishing (Ad)Seres Therapeutics (NASDAQ:MCRB) Upgraded at Wall Street ZenJune 6, 2026 | americanbankingnews.comSeres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of ...June 5, 2026 | finance.yahoo.comSeres Therapeutics Secures $25 Million from Nestlé Health Science and Reduces Facility Costs to Enhance Financial PositionJune 5, 2026 | quiverquant.comQSee More Seres Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Seres Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your email. Email Address About Seres TherapeuticsSeres Therapeutics (NASDAQ:MCRB) is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted. Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection. Seres is also advancing SER-287 in ulcerative colitis, SER-401 in combination with immunotherapy for certain cancers, and other preclinical programs targeting metabolic and inflammatory diseases. The company collaborates with strategic partners, including Nestlé Health Science, to support development, manufacturing scale-up and global research efforts. Founded in 2010, Seres went public in 2015 to further accelerate its clinical pipeline. The management team comprises experienced biotech executives, clinicians and scientists with expertise in microbiome research and product development. Seres continues to conduct multi‐center clinical trials across North America and Europe, seeking to bring first‐in‐class microbiome therapies to patients with limited treatment options.View Seres Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the Show Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.